0001947742-24-000002.txt : 20240326 0001947742-24-000002.hdr.sgml : 20240326 20240326164834 ACCESSION NUMBER: 0001947742-24-000002 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240326 DATE AS OF CHANGE: 20240326 EFFECTIVENESS DATE: 20240326 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Avenzo Therapeutics, Inc. CENTRAL INDEX KEY: 0001947742 ORGANIZATION NAME: IRS NUMBER: 883737798 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-460216 FILM NUMBER: 24784341 BUSINESS ADDRESS: STREET 1: 9171 TOWNE CENTRE DRIVE, SUITE 380 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: (386) 303-1178 MAIL ADDRESS: STREET 1: 9171 TOWNE CENTRE DRIVE, SUITE 380 CITY: SAN DIEGO STATE: CA ZIP: 92122 D/A 1 primary_doc.xml X0708 D/A LIVE 0001947742 Avenzo Therapeutics, Inc. 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 858-239-2944 DELAWARE None None Corporation true 2022 Athena Countouriotis 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Executive Officer Director Brian Sun 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Executive Officer Mohammad Hirmand 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Executive Officer Simeon George 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Director Carl Gordon 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Director Michael Rome 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Director Paolo Tombesi 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Executive Officer Scott Lipman 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Executive Officer Judith Li 12707 High Bluff Drive, Suite 200 San Diego CA CALIFORNIA 92130 Director Biotechnology Decline to Disclose 06b true 0001947742-22-000001 2022-09-14 true true false 0 346850003 223350002 123500001 false 19 0 0 0 false Avenzo Therapeutics, Inc. /s/ Athena Countouriotis, M.D. Athena Countouriotis, M.D. Chief Executive Officer 2024-03-26